Preventive Vaccines Market is projected to be worth USD 94 billion by 2030

Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Preventive Vaccines Market, 2021-2030”.

The report features an extensive study of the current market landscape and future opportunities associated with the preventive vaccine domain. The study also features a detailed analysis of the key drivers and trends related to this evolving segment of the pharmaceutical industry. Amongst other elements, the report includes:

• A detailed assessment of the current market landscape, featuring clinical-stage preventive vaccines.
• A competitiveness analysis of preventive vaccine developers, featuring insightful pictorial summaries and representations.
• Elaborate profiles of the key preventive vaccine developers (shortlisted based on a proprietary criterion) across North America, Europe and Asia Pacific.
• An in-depth analysis of the completed, ongoing and planned trials of various preventive vaccines.
• An overview of the ongoing vaccine development initiatives for complex conditions, such as COVID-19, Ebola virus disease, HIV/AIDS, malaria and zika virus infection.
• An analysis of the investments made in this domain, during the period between 2015 and 2020 (till March).
• A case study on contract manufacturing landscape for vaccines, featuring the CMOs engaged in this domain.

Know more: https://www.rootsanalysis.com/reports/view_document/preventive-vaccines/318.html

A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

Route of Administration

• Intramuscular
• Subcutaneous
• Oral
• Intravenous
• Others

Type of Vaccine

• Pneumococcal Conjugate Vaccine
• Human Papilloma Virus Vaccine
• Rotavirus Vaccine
• Influenza Vaccine
• MMR Vaccine
• Tetanus and Diphtheria Booster Vaccine
• Varicella Vaccine
• DTaP-Hib-IPV Vaccine
• DTaP-HepB-Hib-IPV Vaccine
• Others

Get an Exclusive Sample PDF @ https://www.rootsanalysis.com/reports/318/request-sample.html

Type of Vaccine API

• Live, Attenuated Vaccine
• Inactivated Vaccine
• Conjugate Vaccine
• Subunit Vaccine
• Toxoid Vaccine
• Others

Target Patient Population

• Pediatric Patients
• Adults

Key Players

• GlaxoSmithKline
• Merck
• Sanofi Pasteur
• Pfizer
• Emergent BioSolutions
• CSL
• Others

Key Geographical Regions

• North America
• Europe
• Asia Pacific
• Rest of the World  

Key companies covered in the report

• Bio Farma
• Emergent BioSolutions
• GC Pharma
• GlaxoSmithKline
• Janssen
• Merck
• Novavax
• Pfizer
• Sanofi Pasteur
• Valneva

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4.  Market Landscape

5. Company Competitiveness Analysis

6. Company Profiles

7. Clinical Trial Analysis

8. Ongoing Vaccine Development Initiatives for Complex Conditions

9. Funding and Investment Analysis

10. Market Sizing and Opportunity Analysis

11. Case-in-Point: Contract Manufacturing of Vaccines

12. Concluding Remarks

13. Executive Insights

14. Appendix 1: Tabulated Data

15. Appendix 2: List of Companies and Organizations

Enquiry Before Purchase:

https://www.rootsanalysis.com/reports/318/request-customization.html    

Also Visit Our Latest Publication

Human Microbiome Market

In Silico / Computer-Aided Drug Discovery Services Market

Antibody Contract Manufacturing Market

Biopharma Contract Manufacturing Market

Cell Therapy Manufacturing Market

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Article source: https://article-realm.com/article/Finance/14203-Preventive-Vaccines-Market-is-projected-to-be-worth-USD-94-billion-by-2030.html